Literature DB >> 11104612

The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancer.

X Deng1, E V Høgdall, C K Høgdall, B Nørgaard-Pedersen, M Jørgensen, H Nielsen, S A Engelholm.   

Abstract

OBJECTIVE: The aim of the study was to examine the prognostic values of, respectively, tetranectin (TN) and CA-125 measured in serum from patients presenting with relapse of ovarian cancer (OC).
METHODS: TN and CA-125 were measured in serum samples from 75 patients with relapse of OC before the start of second-line chemotherapy. The endpoint used was death of OC. The variables were analyzed by univariate life table analysis and multivariate Cox analysis.
RESULTS: A significantly shortened survival was found for patients with low serum TN values compared to patients with serum TN levels above one of the cutoff levels. The survivals are illustrated by life tables. No prognostic function was found for CA-125. TN and relapse </=12 months after primary treatment were the only significant independent prognostic variables among the following variables tested in the Cox analyses: primary and second-line treatment, CA-125, age, histology, performance score, tumor localization, and size.
CONCLUSION: Serum TN determination may be valuable in the selection of patients with relapse of OC for new treatment strategies in future studies. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11104612     DOI: 10.1006/gyno.2000.5996

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  Towards an animal model of ovarian cancer: cataloging chicken blood proteins using combinatorial peptide ligand libraries coupled with shotgun proteomic analysis for translational research.

Authors:  Yingying Ma; Zeyu Sun; Ricardo de Matos; Jing Zhang; Kunle Odunsi; Biaoyang Lin
Journal:  OMICS       Date:  2014-03-24

2.  Aberrant tetranectin expression in human breast carcinomas as a predictor of survival.

Authors:  P Obrist; G Spizzo; C Ensinger; D Fong; T Brunhuber; G Schäfer; M Varga; R Margreiter; A Amberger; G Gastl; M Christiansen
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

3.  CLEC3B as a potential diagnostic and prognostic biomarker in lung cancer and association with the immune microenvironment.

Authors:  Jiaxing Sun; Tian Xie; Muhammad Jamal; Zhenbo Tu; Xinran Li; Yingjie Wu; Jingyuan Li; Qiuping Zhang; Xiaoxing Huang
Journal:  Cancer Cell Int       Date:  2020-04-01       Impact factor: 5.722

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.